🔗 Share this article

While the US proceeds with sweeping revisions to its vaccination recommendations, one figure has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based physician and epidemiologist who first made her name by questioning coronavirus vaccinations throughout the global health crisis and has zeroed in on possible deaths following Covid immunization in her short tenure at the Food and Drug Administration.

Proposed Shifts to Pediatric Immunization Schedule

Health officials planned to unveil sweeping changes to the pediatric vaccine schedule earlier this month, synchronizing the US with the Danish immunization schedule, it is understood – a significant shift that would place the US at odds with a large portion of the international standard with no evidence for public health gain. The planned update has been delayed until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is scheduled to speak at the meeting. She was recently named interim head of the FDA’s drug evaluation center, the fifth individual to lead the center this calendar year.

A Shift at the Regulatory Body

This interim role may indicate a strengthened alliance between the drug and biologics branches as Dr. Høeg and Prasad solidify control at the agency – and it points to a increased emphasis upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for ending certain pediatric vaccine recommendations in the US in order to be more similar to the Danish model, a country with universal health coverage and a number of inhabitants approximately the population of the state of Wisconsin.

So far statements, she has continued to focus on vaccination policy – traditionally the domain of Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of medication approval.

Doubts Over Background

Dr. Høeg has no obvious background in drug development, oversight or leadership, which has been customary for past leaders of the biologics center. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“She appears not to have the necessary background” for running the CDER, remarked Jonathan Howard. “She has not conducted a scientific study. She has no expertise in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Previous commissioners of CBER would “be deeply familiar with laws and regulations and the science of pharmaceutical innovation”, noted Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who ran the center have had.”

The drug center has an immense range of responsibilities at the FDA, she emphasized.

“Many people just pays attention on the new drug program, but the off-patent medication office authorizes thousands of generic medications. There is also a biologic copycat branch, non-prescription drug unit and so forth, and each of these must be looked after,” she noted. “The thing you don’t keep your eye on, that is the part that I always told people is going to cause problems.”

Furthermore, a major administrative component to the job, which oversees over 5,000 personnel. “It is a massive management job, if you execute it properly,” the former official said.

Official Statement and Controversial Initiatives

In response to inquiries about Dr. Høeg's qualifications and whether this selection represents greater collaboration among FDA leaders on vaccines, a spokesperson said that the “questions stem from inaccurate presumptions”.

“Her resume matches the duties of her position,” the official explained, noting the time Dr. Høeg spent counseling the agency head on “pharmaceutical safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Høeg assumes responsibility for the commissioner’s controversial priority voucher program, a contentious expedited therapy clearance system that allegedly concerned her predecessors. “How are these therapies being picked for this voucher program? Who makes the calls?” Dr. Howard questioned. “There is a lot of confidentiality occurring at the regulatory body right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards less stringent rules of all drugs, with the exception of shots.”

Public Track Record on Immunizations

With immunizations, Høeg has a more documented, if concerning, past, critics have noted. She released a research paper using non-validated volunteer-provided data to determine the rate of myocarditis after COVID-19 immunization. She advised the Florida top health official Dr. Joseph Ladapo, who was said to have altered data to indicate Covid vaccines are riskier than they are.

Part of her “desired changes” for the incoming administration included changing regulations for novel immunizations and discontinuing “unnecessary” vaccines, she stated post-election on a audio program. At the agency, Høeg has according to sources proposed preventing adolescent males from getting COVID-19 vaccines.

“She is an thorough dogmatist who starts off with her preconceived notions and works backwards to fit the data in a very misleading, dishonest way,” Howard stated.

Taking Control and a “Revenge Tour”

Dr. Høeg joined fellow contrarians, {like|